Uric Acid and Long-term Outcomes in Chronic Kidney Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Patients in the earlier stages of Chronic kidney disease (CKD) are at risk both for the development of end-stage renal disease (ESRD) (define by the requirement for dialysis or kidney transplantation) and development of cardiovascular disease (CVD). Although controversial, there is literature to suggest that uric acid may play a role in the progression of kidney disease and development of cardiovascular disease (CVD). The Modification of Diet in Renal Disease (MDRD) Study was a randomized controlled trial in patients with CKD, which examined the effects of dietary protein restriction and strict blood pressure control on progression of non-diabetic CKD. Extensive data on risk factors for progression of kidney disease and development of CVD are available, as is long term follow up. 838 of the 840 patients who were randomized have uric acid levels measured at baseline. The aims of the present study are to examine the determinants of uric acid in cross sectional analysis at baseline, to determine the association between uric acid and development of ESRD, and the association of uric acid with all-cause and CVD mortality.
Level of kidney function will be a major determinant of uric acid levels independent of other risk factors.
Level of uric acid will be associated with development of ESRD independent of level of kidney function and other risk factors.
Uric Acid levels will be associated with both all-cause and CVD mortality independent of kidney function and other risk factors.
| Condition |
|---|
|
Chronic Kidney Disease |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Does Uric Acid Promote Progression of Kidney Disease and Development of Cardiovascular Disease in Patients With Chronic Kidney Disease? |
- Kidney Failure
- CVD and All-Cause Mortality
| Enrollment: | 838 |
| Study Start Date: | February 2007 |
| Groups/Cohorts |
|---|
| non-diabetic Chronic Kidney disease |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
838 participants of the randomized arm of the Modification of Diet in Renal Disaese (MDRD) Study conducted between 1989-1993
Inclusion Criteria:
- between 18 and 70 years of age
- with serum creatinine of 1.2 to 7 mg/dl in women and 1.4 to 7 mg/dl in men
Exclusion Criteria:
- pregnancy
- Type I diabetes
- insulin dependent type II diabetes
- renal artery stenosis
- proteinuria greater than 10mg/day
- mean arterial pressure greater than 125 mmHg
- prior kidney transplant
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Mark Sarnak, MD, Tufts Medical Center |
| ClinicalTrials.gov Identifier: | NCT01158911 History of Changes |
| Other Study ID Numbers: | 4530 |
| Study First Received: | July 6, 2010 |
| Last Updated: | July 7, 2010 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Tufts Medical Center:
|
kidney disease uric acid outcomes cardiovascular |
mortality kidney failure Uric Acid levels in patients with Chronic Kidney Disease |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Kidney Diseases Renal Insufficiency, Chronic Kidney Failure, Chronic Urologic Diseases Renal Insufficiency |
Uric Acid Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 16, 2013